Global Multi Infarct Dementia Market - Analysis, Technologies & Forecasts to 2022 - Rising Prevalence of Stroke Driving Growth - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022" report to their offering.

American Stoke Association, in its 2016 epidemiological report on stroke, projected the global prevalence rate of stroke accounted for one in five per 1000 person. In U.S. nearly 800,000 people have a stroke every year, according to American Stroke Association. By 2030 stroke prevalence will rise around 20% more than 2012 level. There are no practicable treatment options for multi infarct dementia, other than early diagnosis and routine therapy.

Increasing geriatric population, rising prevalence of strokes and increasing healthcare spending are the growth drivers discussed in multi-infarct dementia market research report. Emerging Economies and technological advancements in inhibitors are opportunities in deliberated in multi-infarct dementia market report for the forecasted period.

Varying regulatory environment of different countries and unavailability of treatment therapy are the restraining issues discussed in multi infarct dementia market report. Lack of awareness about dementia as a disease is a challenge for the market growth.

North America is the largest market for multi-infarct dementia market followed by Europe. Increasing cases of multi infarct dementia and growing geriatric population are the factors driving multi-infarct dementia market in the region. Multi-Infarct Dementia accounts for 30% of all dementia cases in North America and Europe.

Asia Pacific is the fastest growing multi-infarct dementia market for the forecasted period. Rising geriatric population, increased healthcare spending, and changing healthcare reforms are the factors driving multi-infarct dementia market in the region for the forecasted period. Multi-Infarct dementia accounts for over 50% of the dementia cases in Japan.

Companies Mentioned:

  • Accelerys Inc.
  • Affymetrix
  • Agilent Technologies
  • Celera Corporation
  • Dnanexus
  • Forest Laboratories Inc.
  • Geneva Bioinformatics
  • Gvk Biosciences
  • Ibm Life Sciences
  • Illumina Inc.
  • Janssen Pharmaceuticals Inc.
  • Life Technologies Corporation
  • Novartis Pharmaceutical Corporation
  • Pfizer Inc.
  • Siegen Inc.

Key Topics Covered:

1. Introduction

2. Market Overview

3. Market Determinants

4. Market Segmentation

5. Competitive Landscape

6. Global Multi-Infarct Dementia Market By Region (Revenue Analysis) 2014-2022 ($ Million)

7. Company Profiles

For more information about this report visit http://www.researchandmarkets.com/research/4szldb/global_multi

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716